FDA Accepts New Drug Application For Taletrectinib in ROS1+ NSCLC
FDA Reviews NDA for Dordaviprone in Recurrent H3 K27M-Mutant Diffuse Glioma
AYA Patients With Cancer, ‘In Between’ Kids and Adults, Face Unique Concerns
CAR T-Cell Therapy Yescarta Continues to Demonstrate Durable Responses in Follicular Lymphoma